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23 A.  SlJMMAI{Y 
The  1997  report  is  the  rourth annual  report or the  ( \munission on  the  development  and 
validation  or alternative  methods  to  animal  testing  in  cosmetics.  The  previous  year 
represented a landmark in the field of  alternative test methods in cosmetics.  · 
' 
Following  the  efforts  that  had; been  made  in  method  development,  results  from  the 
~arious programmes were a little· disappointing in some fields.  Therefore, with regret, it 
was  necessary to  postpone the  implementation of the prohibition of animal  testing ·on 
cosmetics  from  1 January 1998  to  30 June 2000.  this  was  due  to  the  fact  that 
scientifically  validated  alternative  methods  to  animal  testing  of cosmetics  were  not 
available. 
Competence for the  Cosmeti~s Directive was transferred from DG XXIY to  DG III, and 
the  scientific  committee  that  advises  the  Commission  on· the.  SC!fety  evaluation .of 
cosnietics undc~ent  a fundamental restructuring. 
In  scientific  terms,  some  very  good  progres~ was  made.  The  second  phase  of an 
EU/COLIPA (The Eur.opeari Cosmetic, Toiletry and Perfumery Association) international 
validation study was successfully completed, and the scientific validity of  the 3T3 neutral 
red  uptake  phototoxicity  (NRU PT)  test  was  ~ndorsed by  the  Commission's  expert 
services.  Also,  an  international  validation  study  on skin  corrosivity  co-ordinated  by 
ECV AM was  successfully ·completed, and two test methods were judged to  have been 
scientifically validated. 
New research proposals are now under development,_ to continue the efforts made to date. 
, The  cosmetics  industry  continues  to  be  one  of the  main  focus  points  of alternative 
method  development.  The  best  available  estimates  demonstrate  that  approximately , 
35,000  animals  are ·used  in  the  EU  each  year,  for  the  specific  purposes  of testing 
cosmetics. ·  This is less than one perce~t of  the estimated ten million animals used in the 
EU each year in experimentation.  Not all of these animals are necessarily used for tests· 
conducted to  meet the  requirements of the· EU  Cosmetics Directive 76/768/EEC; tests 
may  also  be  conducted  in  order  to  satisfy  .the  requirements  of different  sectoral 
legislation. 
. 
In spite of  the relatively !ow number of  animals used for the testing of  cosmetic products, 
the industry has often been ai the forefront of research activities in recent years.  Further, 
the  Commission  services  have  devoted  significant  reso\rrces · to  the  replacement  and 
. reduction of  animal testing in the cosmetics industry.  · 
3 B.  INTRODUCTION 
The  1997 Annual  report  on  the  development,· validation---and  legal  acceptance  of · 
· alternative methods to  animal. experiments in the field of cosmetics is the  fourth  report -
presented by  the· Commission.·  It.  presents the scientific and-regulatory situation in  the 
development and validation of  alternative methods in cosmetics as of Decem her i 997. 
.  .  ' 
The  repott is  produced in  .o~der to  comply with Article 4 (1) (I)  of the EU  Cosmetics 
Directive. 76/768/EEC which states that,  ·  · 
'The Comm~ssion shall present an  annual report to the European· Parlia11Jent  and the 
Count:; if on progress in  the development,· validqtion and legal acceptance of  alternative· 
· "method.,  to ihose involving experiments on animals.  That report shall contain precise 
data on the number and type of  experiments relating to cosmetic products carried out on  . 
animals.  The  Member States shall be obiiged to  collect that information in addition to 
collecting statistics as laid d()wn  by Directive 86/609/EEC on the protection of  animals . 
. used. for  experimental  and scientific  purposes.:_  The  Commissiqn  shall  in ·parti~ular 
.  · . ensure the development,  validation and legal al;ceptimce of  experimental methods .which 
do noi use live animals. " 
The 1997 repQrt therefore outlines the status of  alternative methods at the end ofthe year, 
· a year in which it was necessary for the Commission to postpone the proposed ban. on the 
marketing of cosmetics containing ingredients and combinations of ingredients that had . 
been  tested  o~  · animals,  based  on  expert  sci~ntific  advice.  The  context·  of the .. 
postponement -is  discussed,  and· recent progress in the  development and  validation of 
alternative methods is reviewed.  .  .  .  . 
Data Ori animal usage for the testing of  cosm~tic  'materialsjs presented, for the past three . 
·.  years.  An examination of the. problems associated with. compilation-of  these data 'is also 
given. ·  Lastly,  co_nclusions  on. the  current  status  of the  development  of alternative  / 
methods are given  .. 
. C.  COMPETENCE FOR COSMETICS-IN 1997 
1997 was an important year for cosmetics legislation within' the European Commission, 
both from an administrative an4 technical·yiewpoint.  In recent years, responsibility for 
the cosmetics· dossier resided under the competence of DG XXIV.  :However, early in.  .  .  . 
1997 the Commission reviewed procedures within its administration and a reorganisation 
in. the responsibilities of its services wrui initiated.  This was primarily to meet th~ needs 
of the  Commission. in  differentiating. those  services responsible for the  .. provision _of 
scientific advice :from th'?se Services responsible for legislation:  · 
4 From  1st  April  1997  the  Cosmetics  Directive  was  moved  from  DG XXIV  to  DG  III 
(Industry), which is  headed by Commissioner Bangemann.  The Directive is  now  under 
the  responsibility  of  Unit  OG 111/E/3  which  is  also  the  competent  gnn1p  for 
pharmaceutical  legislation ·in  Europe.·  DG Ill  is  the  Commission  service.  that  holds 
· competence  for  all  legislative  measures  relating  to  the  EU  Cosmetics  Directive 
76/768/EEC including provisions r~lating to the use of  ~imals in the testing of cosmetic 
products  and  ingredients.  In  this  context,  DG III  is  also  responsible  for  the  An'nual 
Report  on the  development,. validation and  legru  acceptance of'  alternative methods  to 
animal experiments with cosmetics .. 
The  services .  of DG XXIV retained responsibility for  the management of the  scientific 
· committee that advises the Commission on scientific matters_relating to cosmetics safety, 
namely the Scientific Committee on Cosmetology (SCC).  Therefore, DG XXIV is  now 
responsible for  providing scientifi<:  advice on the safety o.f cosmetic ingredients to  the 
Commission. 
The  SCC  also  underwent a  fundamental  restructuring. in  1997.  The  Committee  was 
or~ginally  created  to  meet  the · provisions  of  Commission  Decision  78/45/EEC 
establishing a Scientific Committee on Cosmetology.  The mandate of the  SCC expired 
in  October I 996,  although  the  Committee  continued  to  fulfil  its  role  during  the 
Commission's re-organisation of  its scientific services.  · 
Commission Decision 97  /579/EC outlined the requirements for setting up the SCientific 
Committee  on  Cosmetic  Products  and  Non._Food  Products  (SCCNFP)  intended  for 
Consumers, as  one of eight new committees.  The  membership of the new committee, 
SCCNFP was published in the Official Journal on 12 November ·1997.  In its first Plenary 
meeting  of 14 November 1997,  the  specific  working  party  on  alternatives  to  animal 
testing was established. 
The SCCNFP shall, through the advice-o{the working group on alternatives to animal 
testing, act as  an expert resource to  the European Commission in the development and 
applicability of alternative methods to animal testing in cosmetics.  Upon the request of 
-the  Commission  services  they  wilt. review  data ·submitted  on  alternative  methods  to 
animal 'testing that have  been assessed and  validated  by  the  services of the  European 
Commission,  or c.outd  be  considered  appropriate  for  the  replace-ment  of test  methods 
using animals. 
One of  the most important aspects of the responsibilities. of this work will be to advise 
the European Commission on the status of alternatives to animal testing in cosmetics on 
an  on-going  basis  and  in  particularly,  in  accordance  with  Article 4 (1) (I)  of the 
EU Cosmetics Directiye 76/768/EEC. 
D.  POSTPONEMENT  OF  THE  DATE .FOR  PROHffiiTION  OF  ANIMAL 
TESTING FOR COSMETICS 
As  concluded in  the 1996 report, a Directive was drawn up by the Commission which 
postponed  the deadline  of 1 January 1998  for  the  prohibition  of animal  testing  'of 
cosmetics.  This Directive was proposed after extensive consultations Within the services 
of  the Commission and was required to meet the following considerations: 
5 .  /  '  . 
~  The m~in  objective of  the Cosmetics Directive 761768/EEC is to protect public health 
and it is therefore indispensable to carry out certain toxicological tests to evaluate the 
safety  for  human  health  of ingredients . and  combinations  of ingredients  used ·in 
c·~smetic product formulations:  .  ·  .  - ' 
=  The development, validation .and acceptance of alternative methods proved to  be  m1 
.. extremely: complex scientiiic challenge.  ht particular; the  timetable for the various 
· stages  of  the  development  and  vali~ation  process  had  . previously  been 
underestimated, as exemplified'by the·n~ed for pre-validation studies. 
o  Progress  had . been  maqe  in  research  into  alternative·  methods  to  animal· testing,. 
particularly  in  the  end-points  of percutaneous  absorption,  phototoxicity  and  local 
risks  to  the  eyes  and  skin.  However,  no  alternative  testing  methods  had  been 
scientifically  validated  and  the  OECD had  not  adopted  guidelines  for  any  toxicity 
. tests using non-animal methods. 
.  .  . 
Whilst it  was not possible to  foresee  th~. date by  which alternative methods for testing 
ingredients  and  combi~ations of ingredients. for  risk  to  human  health  would· b.ecome 
'available for ail·toxic end-points, it was equally important not to excessively delay the 
timings. for  scientific reassessment of the situation.  Therefore, Commission Directive 
97/18, published on t  st May 1997, postponed the ban-on animal testing of cosmetics and-
their combinat}ons until 30 Jtine 2000.  Most importantly, the publication of  this Decision 
in .  no  way prejudiced -the  objective of reducing· the  number of test animals-and  their 
suffering.  In'this respect, the Commission committed itself to the promotion of  research 
and validation of  alternative methods. 
The revised wording of Article 4 of tlie EU Cosmetics Directive 76/768/EEC states that 
Member States shall prohibit the marketing of  cosmetiC products containing: .. 
''ingredients  or- combinations of  ingredients  tested. on. animals  after  30 June 2000  in 
order to meet the requirements of  the Directive.  .  .  ..  . 
'  ,  -
If  there  has  been .  insufficient progress  in  developing  satisfactory  methods  to  replace 
animal testing,  and in particular to  those  cases where  alternative  methods of  testing, 
· despite all reasonable ,endeavours,  have not been scientifically validated as offering an . 
~equivalent level of  protection for ·the consumer,  taking into accoimr  OECD toxicity' test 
guidelines, the Commis-sion shall, by 1 January 2000, submit draft measures to postpone 
· the  date of  implementation of  this provision, for those· test methods ·in respect of  which 
there  has  been  insufficient progress ·in  developing alternative  methods,  in Article 10. 
Before submitting such ·nieasures,  the Commission will consult the Scientific Comrnittee 
on Cosmetology. "  '  ~  ·  . 
The situation regarding the availaqility of alternative methods to-animal testing did not 
change  in  the  meantime,  indicating  that  the  postponement,·  as .  proposed  by  the 
.Commission and agreed by the Council of  Ministers; was appropriate . 
. Foliowing this .postponement, there was a ,clear need  for  new initiative's in the field· of 
· animal testing for cosmetics.  ~  :- . 
6 As  the  experimental  phases of many  validation studies have  drawn to  a close, experts 
have  examined  the  extensive  databases  generated  in  order  to  determine  the  most 
promising next steps.  Also, a nwnber of expert workshops have b~en convened in order 
to assess progress to date and identify promising leads from  ~ecent research progran1mes. 
·  ~l~he  Commission  will  now,  contribute  to  and  closely  monitor  the  development  and 
regulatory  acceptance  of alternative  methods  over  the  next  18  months·  in  order  to 
determine whether the. requirements of  Article 4 can be met in line with the timings given 
i.e.  whether  ·scientifically  validated  ·alternative  methods  will  be  available  by 
· January 2000.  This guidance will come from  the Commission s,ervices responsible for 
the developments and validation of such methods, .and on the basis of the advice of the 
SCCN FP regarding the acceptability of  alternative methods to animal testing in the safety 
'evaluation of  cosmetics..  · 
E.  INITIATIVES TAKEN IN 1997 
ECVAM 
ECV  AM continued to  promote  the  scientific  and  regulatory acceptance of alternative 
methods which are of importance to the biosciences and which reduce, refine or replace 
the  use of laboratory animals throughout  1997. ECV AM's major achievements during 
_.  1997 related to the following, in accordance with its duties as a source of scientific and 
technical support to other Commission.services: 
ECVAM's main validation activities in  1997  involved two  international  studies.  The 
first was the completion of  the formal validation phase of  an EU/COLIP  A study on an in 
vitro phototoxicity test which is now considered by the Commission to be a scientifically 
validated test which  is  ready to  be  considered for  regulatory  acceptance.  Jbe second 
study  was  a validation  study on in  vitro  tests  for  skin corrosivity from  which  it  was 
concluded by the ECV AM ·Management Team that two of  the methods can be considered 
as scientifically validated for use as replacements for the animal' test for distinguishing 
between corrosjve and non-corrosiye chemicals. 
In addition, a validation study. is ongoing in the endpoint of embtyotoxicity testing.  A 
further prevalidation study on haematotoxicity testing has been initiated which will assess 
the granulocyte-macrophage-colony forming unit (GM-CFU) test for acute neutropenia. 
The validation of  new test methods, in terms of assessing their·relevance and reliability, 
requires  the  application  of biostatistical  methods  and  close  collaboration  between 
biostatisticians and experimental scientists.  ECVAM's biostatistician played a key role 
during the successful validation study on in vitro-tests for skin corrosivity, having input 
· into the  study design and being responsible for the data collection and analysis stages. 
The ECV AM Biostatistics Task Force ·continues to  develop and  ~valuate. new ideas for 
improving the analysis of data obtained from alternative tests during validation studies, 
through the proper application of biostatistical techniques. In particular; the importance 
of developing and assessing prediction models,  for  interpreting the data obtained with 
alternative methods in relation to known in vivo effects, was demonstrated during 1997 .  .  ,  .  . 
One of ECV AM's priorities is to, ensure that it is well informed about the state of the art 
of non-aninial test deve'lopment an~ validation. ECV  AM workshops are therefore held to 
7 review the current status of various types of alternative tests and their potential uses, and 
to  identify  the  best  ways  forward.  The  reports  and  recommendations  of  ECV J\M 
workshops are published in international scien_tific journals. During 1997, five workshops 
were held, on:  .  ·  ·  . 
Th~-lJse ofTransgenic Animals in the European Union; 
•  ·Issues Relating to the Release of Proprietary Information and Data for Use in the 
Validation of  Alternative Methods; 
•  Non-animal (Alternative) Tests for Evaluating the Toxicity of  Solid Xenobiotics; 
•  The_Use of Human Keratinocytes· and Human Skin Models for Predicting Skin 
Irritation; and 
--Validation of_Alternative'Methods for the Potency Testing of  Immunobiologicals. _ 
ECVAM  Task  Forces  have  been established on. topics of importance to ECVAM  (for 
example, on biostatistics, prevalidation, skin  irritation,  and  developmental  toxicity},  to 
focus  on more specific issues,  such as  the actual  design of ,prevalidation -or  validation 
studies.  · 
ECVAM's Scientific Information Service (SIS) has developed a-database on alternative 
methods.  · This database contains information on their uses, their state of development 
and validation encompassing details. of  the methods, test chemicals and results as 'well as 
literature  references.  A  second  database  has -been  developed  on  validation  studies . 
(dbVas-online  )~ which provides support for  ECYAM's validation studies and includes 
information  on  participating  organisations,  test  protocols  and  prediction  models,  test 
chemicals and results. Access -to  db Vas-online will be via the Internet (general access) 
_·and  Intranet (access ·restricted to  particip1,Ults  in on-going validation studies).  A third 
database on in  vitr~ pharmacotoxicology laboratories is at the planning stage. 
Collaborative experimental studies with groups in  the· EU  Member States, focusing on· 
the evaluation and prevalidation of new ~n vitro.tests, are also bei~g undertaken.  A study 
on  embryotoxicity·testing in  vitro  with embryonalstem cell  lines  aims to  characterise . 
native and engineered embryonal stem cell lines for the development 0fmore·specific and 
more sensitive endpoints for embryotoxicity. 
There is also a study on the characterisatio~ and use of  genetically engineered cell lines in 
research into metabolism-mediated toxicity.  The study will--characterise and evaluate the 
applicability of various  ge~etically' engineered miunmalian cell lines that express human 
cytochrome P450 isoforms. 
'  ' 
Lastly, a study is on-going o_n the identification and evaluation of  new endpoints for use 
in  an  in  vitro  nephrotoxicity  screening test.  In this  programme,- the  integrity of renal 
epithelial cells grown on microporous supports following exposure to chemicals is being 
assessed by measuring several markers of  epitheiial barrier function. 
· Irt  .addition  to  these  laboratory  studies,·- other  projects  are'  being  undertaken  in 
coll<iboration with scientists in the EU Member States such as a review on the scientific, 
ethical and legal aspects of  the production,· breeding and use of  transgenic animals.  Also, 
projects are underway looking at the use of human volunteers in assessing the efficacy. 
and  safety  of cosmetic  products  and  ·at  the  use  of  mathematical  models  in  the 
development and validation of  non-animal tests and testing strategies.  .·  . 
8 DG III 
DG  111  took  over responsibility  for  the  Cosmetics  sector  in  1997.  Since  then.  it  has 
IK~l:OIIIl'  active  in  the  Commission's  work  on  1111:  lkvclopmcnl  ami  acl:qllalll:l'  of 
alternative  methods.  DG Ill  is  represented  on  ESAC  and  has  been  proposed  for 
participation in the ECVA.M Management Board; DG III will also participate in relevant 
ECV AM workshops.  Also, it collaborates with the other Commission services that work 
in the field of  alternatives such as DG XXIV, DG XI and DG XII. 
DG III now holds responsibility for the preparation of the annual report and coq.sequently 
for  the  compilation of data on animal  experimentation  for  cosmetics  within the  EU. 
· Further to  several communications reminding Member States of their obligations in this 
respect, DG III  is now considering infringement procedures against some Member States 
that have_ failed to meet these obligations to date.  · 
In  terms of future initiatives from DG III, international discussions in the field of animal 
testing of cosmetics have been identified as a high priority.  An integral part of DG III's 
future work programme will be ~e  discussion of  the issue of animal testing of  cosmetics 
at  an  international regulatory· level.  The intention of such discussions will  be  to  raise 
awareness of the  on-going efforts  in  Europe  and  facilitate  the  international  regulatory 
acceptance of  alternative methods. 
DGXI 
DG XI  holds responsibility for Council Directive 86/609/EEC on the approximation of 
laws,  regulations  and  administrative  provisions  of  Member  States  regarding  -the 
protection of animals used for experimental and other scientific purposes.  Pursuant to 
Articles 13  and 26 of this Directive, DG XI  presents to the Council and the European 
Parliament statistical data on· animals used for experimentation in the EU.  The second in 
this  series  of reports ·is  currently  in' preparation  on ·the  basis  of data  submitted  by 
EU Member States. 
In the latter half of 1997, the Member States agreed to a uniform format for presentation 
of these data allowing for a harrnonised compilation method throughout the  EU.  This 
method will be applied. in the thir9 Commission rep.ort foreseen for the year 2000. 
'  -
In addition, DG XI takes a lead role along with ECVAM, in advising the· Commission on 
the validation of alternative methods.  To this end, DG XI and ECV  AM produced a joint 
endorsement statement on the in vitro test for phototoxic potential, stating·that this. test is 
now scientifically validated and ready for regulatory acceptance. 
· In 1997, DG XI took the initiative on several occasions at OECD in relation to alternative 
test  methods.  These  initiatives  include  the  forwarding  of  the  above-mentioned 
endorsement  to  the  OECD  secretariat,  the  pressing  for  a  deletion  of OECD  Test 
Guideline 401  for  the  determination  of LD 50  and  the  continued  promotion  of the 
acceptance of  the in vitro method for percutaneous absorption. 
9 DG XII 
In  1997, DG XII continu9d to prorrio,te research in the field of "Prenormative research: In 
.  vitro  alternatives to  animal  experiments in pharmaco-toxicology" under the  BIOTECH 
and BIOMED programmes.  ·  · 
\ 
BIOTECH 
The following projects are currently funded across the 4 topics contained in the sector "In  . 
vitro" alternatives to animal experiments, for a total of 13,006,400 ECUs. 
r  .  ,  ,  ' 
"In vitro" tests for developmental pharmaco-toxicology: 
- Development of in vitro mammalian germ cell culture systems and genetic markers for 
· reproductive pharmaco-toxicology 
- Development and  evaluation of Leydig cell  lines as  in  vitro  models for  toxicological 
testing 
"In vitro" tests for neuro-pharmaco-toxicology: 
-New im~uno-pharmaco-toxicological model: human·reconstructed epidermis containing 
Langerhans cells  .  · 
- Development  of in  vitro  tests  for  drug  allergenicity  and  Bcell  switching  to  IgE 
synthesis·  .  . 
-_Development of  in  vitro systems using human immortalised cell lines for testing skin 
irritancy  .  .  . 
- Establishment of  stable immortal differentiated cell lines for the development of in vitro 
tests 
Immuno-pharmaco-toxicology 
·- In  vitro  neurotoxicology  tests  based  on the  coupling  of brain  slices  to  silicon 
microelectrode arrays  .  .  .. · 
:..  Novel human renal and  hepatic co-culture  in  vitro test systems  for·the evaluation of 
biotechnology-derived cytokines ,  · 
- Development pf 3D  in  vitro  models  of human  tissues  for  pharmaco-toxicological 
applications 
Cell cultures for the development ofin vitro tests 
- Developincnt  of a  yeast-based  model  system  for  expression  of higher  eukaryotic 
K+ channels and their pharmacological analysis 
- New developments of  cultured precision-cut tissue slices for studies of  organ pharmaco-
toxicology  · 
. Three .new projects 'successfully evaluated during the fourth and last call for proposals are 
now undergoing.negotiation.  ·  · 
Four projects are directly contributing to increasing scientific knowledge which may lead 
to the implementation in the Cosmetic Directive 76/768/EEC. 
' 
In order to ensure the exploitation and industrial relevance, close interactions with IVTIP 
are  encouraged.  The "In· vitro  Testing  Industrial  Platform"· wa's  funded in 1993  by 
19 European .  companies  with  activities ·in  th~ (pharmaceutical,  chemical  and  cosmetic 
sectors.  Industrial 'platforms are techriology-driven industrial groupings established on 
'  .  . 
the initiative of industry around Biotechnology RTD contracts, that monitor EU-funded 
( 
10 research and advise the European Commission on industrial requirements in the specific 
sector of  interest. 
Interactions  with  ECV AM  have  been  ensured.  Currently,  two  tests  resulting  from 
EU Biotechnology  programme-fundt;d  projects  have  been  transferred  to  ECVAM  for 
further evaluation.  These are: 
_  •  Predictive test for ~xcitotoxicity 
•  In vitro nephrotoxicity testing and epithelial barrier functions 
BIOMED 
The following in vitro tests are currently funded in the area of  "Pharmaceutical research" 
for a total of 3,820,000 ECUs:  · 
- Molecular  and  cellular  mechanisms  of photoxicity:  multidisciplinary  strategy  for 
predicting in vitro the phototoxic risk of  new .drugs 
- Evaluation of  oculotoxicity of  drugs in vitro 
- Vaiidation of an  in  vitro .  assay to  evaluate drug effects on synaptic functioning and 
plasticitY 
- Integration of in vitro approaches to predict drug metabolism and interactions in man in 
the development ofpharmaceuticals 
Lastly,  funding  for  three  RTD  projects  of the  Standards,  Measurements  and  Testing 
programme was maintained during 1997: 
. SMT4-CT96-2070  . Development of standardised in vitro methodology for hepatic and 
renal toxicity testing 
SMT4-CT97-2152  Measurements to  assess  the  efficacy of sunscreens  in  industrial 
research 
SMT4-CT97-2174  Testing  and  improvement of reconstituted  skin  kits  in  order to 
elaborate European standards 
Jn 1997, DG XII prepared the proposal for the 5th Framework Programme for a decision 
in  1998 by the European Parliament and the Council.  The first call for· tender could be · 
issued around the end of the year.  Provision for the funding of  research into alternative 
test  methods  will  be  exainincd  in  the  drafting  of the  work  programme  of the  theme 
"Quality of  life and management ofliving resources"-Key action: "Cell factory." 
DGXXIV 
The management and work program of  the scientific committees that advise the European 
Commission fall under the responsibility ofDG XXIV.  Consequently, DG XXIV plays a 
pivotal  role  in  the  provision of scientific  advice  to  the  Commission services.  Most 
.  notably, in the field of cosmetics, DG XXIV manages the SCCNFP (formerly the SCC), 
which advises the Commission,on the safety of  cosmetic materials. 
Since  the  publication  of the  previous  Annual  Report,  the  SCC  adopted  the  s~cond 
revision (XXIV  /1878/97) of their "Notes of guidance for testing of cosmetic ingredients 
for their safety evaluation."  Annex 8 of  these guidelines, "The use of  methods alternative 
to  animal  studies  in -the  safety evaluation of cosmetic ingredients  or combinations of . 
ingreaients," discusses the status of alternative. methods.  The SCC notes reviewed the 
11 data obtained from  the variOl1S  validation studies that had recently been completed.  The. 
·SCC  review concluded  that there  were  good  prospects  for  alternative  methods .in  the 
fields of  skin irritation, ·percutaneous absorPtion and phototoxicity.  .  · 
.  . 
Through  another  initiative,  the  SCC  discussed  the. ethical  considerations ·of tests  on 
humans. 
OECD  .  .  .  .  :  (. 
· In  September 1996, the ih National Co-ordinators meeting endorsed the recommended 
· validation and acceptance criteria that followed the OECD Solna workshop,· and agreed 
that  a  guidance  document  should  be  drafted  on the  validation of new  test  methods. 
Further,  a  document  on  the  validation  of test  methods  considered  for  .adoption  as 
OECD test  guidelin~s has been prepared arid will be discussed in ah OECD meeting of 
the Chemic_als Group and Management Committee in early 1998. · 
.  . 
The OECD _continued  its lead in the discussions over percutaneous absorption and the. 
development of  test guidelines.  The latest summary of  the test guidelines was discussed 
at  the  8th National·· Co-ordinators  nieeting  and  later  at  a  meeting  of the  Steering 
·committee during 1997. 
- COLlPA 
During  1997,  CO  LIP A worked  on  guidelines  for  the  training of SMEs in  the use  of 
alternati~e methods for  safety assessment and in· interpretation of their results.  ·These 
guidelines and training programmes will be essential to the dissemination of information 
oh alternative methods arid to .the acceptance of  their use. 
COLIPA have contributed to the exhaustive reviews ofthe databases on skin penetration 
and eye irritation that have been carried out in the past year, including d~ta reviews from 
the  respective  validation· studies.  In  the  area  of skin  sensitisation,  CO  LIP A  have 
reviewed the current database on mechanism of action and wil1 propose studjes to begin 
in ·1998. 
Following the disappointing results of the studies to evaluate methods for eye irritation, 
CO  LIP  A held an expert symposium in October 1997 to discuss the results obtained to 
date, analyse mechanistic theories and propose next steps.  The report of  the meeting Will 
be available in early  1998 and will form the basis ofthe next round of studies on eye. 
irritation.  ·  · 
Du:ring  1997, the SCAA  T team of CO  LIP A· reviewed and refocused its strategy on the 
development of alternative test methods,  in order to  ensure that appropriate resources 
were  allocated  to the priorities of the cosmetics industry.  The SCAAT strategy is  to 
· ·make the_ cosmetics sector the "lea,d" industry in the development qf alternative tests in 
those end-points that are relevant to cosmetics, namely:  .  · 
-·skin and eye irritation- · 
- skin absorption 
- skin ·sensitisation 
- phototoxicity 
12 Over the short to  medium· term, skin irritation, skin penetration, phototoxicity and  skin 
corrosivity are priority topics and will be allocated 60% of the organisation's resources. 
'Eye irritation, skin sensitisation and photoallergy will  devel~ped over the medium ~o long 
term since they involve research into the mechanisms of  action.  SCAA Twill not activdy 
work  on  the  development of tests  for  systemic,  teratogenic or carcinogenic end-points. 
although initiatives in this field will be monitored in order to assess any application to the 
testing of  cosmetic ingredients.  ·  · 
. F.  CURRENT STATUS OF DEVELOPMENT OF ALTERNATIVES 
Phototoxicity 
This  year has  seen the  completion of the  data. analysis  for  the  Phase II  study on .  the 
validation of  the 3T3 NRU PT test.  This is a cytotoxicity test in which UV sensitivity of 
Balb/c 3T3 cells is determined by their capacity to take up the vital dye, neutral red.  If 
the toxicity of a chemical increases significantly in the presence of UV  A, the chemical 
can be considered as having a phototoxic potential. 
The  data  analyses. confirmed  the  reliability  and- relevance  of the  test  for  predicting 
phototoxic effects and  identifying phototoxic chemicals.  Two forms  of the  statistical 
model were applied to the data in test on 30 chemicals in 9 laboratories, namely the PIF 
· (Photolrritation Factor and the MPE (Mean Photo Effect):  On comparison of  the in vitro 
classifications with the in  vivo classifications assigned to the chemicals before the trial 
began, the following statistical parameters were found:  ·  ·· 
PIF  MPE 
Specificity  90%  93% 
Sensitivity  82%  84% 
Positive predictivity .  96%  96% 
Negative predictivity  64%  73% 
Accuracy  88%  92% 
Consequently, the  ECV AM. Scientific Advisory  Committee unanimously endorsed  the 
following  statement  , agreeing with. the  conclusion of the  Management Team,  on  the 
scientific validity of  the 3T3 NRU PT test, at its 9
1 !
1 meeting on 1-2 October 1997: 
.  .  ' 
The results obtained with the 3T3 NRU PT test in the blind trial phase of the 
EU/COLIPA  international  validation  study  on  in  vitro  tests  for  phototoxic 
potential were highly reproducible in all  the nine laboratories that performed 
the test, and the correlations between the in vitro data and the in vivo data were 
very  good.  The  Committee therefore  agrees  with the  conclusion  from  thi.s 
formal  validation study that the 3T3 NRU PT test is a scientifically validated 
test which is ready to be considered for regulatory acceptance. 
The study was conducted in accordance with general scientific principles laid down in 
various · ECV  AM/ERG  A  TT  workshops  and  the  criteria  recommended  at  an 
OECD workshop held in 1996. 
13 · Other methodologies included·in this validation trial were: 
o  the SOLATEX PT test 
•  the histidine oxidation test 
•  a protein binding test 
the Skin
2  ZK 1350 PT test 
o  a complement PTtest 
•  I! hum(ln keratinocyte test 
•  the Red Blood Cell (RBC) phototoxicity test 
Some  of these  methods  showed-potential  as  tools for  mechanisti-c  testing  an:d  may be 
investigated fu~her.  These results will be published in a later report, which will discuss 
the  use  of ·the  methods  for  distinguishing  between  different  types  of phqtotoxicity, 
estimating  phototoxic  potencies  and ,differentiating  photoirritan,t  and  photosensitising 
cheiriicals.  In  addition,  data  from  the  application  of the·  NRU PT  test  to  humap 
_  keratiilocytes has been used in the development of a method to compare .dose response · 
curves. 
The SCC requested a study to confirm whether the 3T3-NRU PT test is  suitable to test 
UV-filters~ as regulated in Annex VII of the EU.Cosmetics Directive 761?68/EEC.  This 
was considered an  additionaf study rather thim  constituting· a further part of the formal 
validation programme·.  _ 
.  .  .  .  . 
The biometrical analyses referred to in the 1996 Commission Report suggested that the 
predictivity of  the model could be improved by using more .detail from the area under the 
concentration response curves than by determination of  the PIF (Photolrritation FaCto I} 
Therefore, bot~ the MPE (Mean Photo Effect) and the PIF were me~ured  in this study: 
The  study  was  funded  by  ECV  AM  and  managed- by the  contractor,  ZEBET.  The 
expe:rimental  procedures were  either performed ·by' ZEBET  or contracted  out to  third 
parties.  - The  study  involved  the  testing  of 20 chemicals  _  (10 photoirritants, 
1  0 non-photoirritants' of which  8  were  OV  filters),  each of which was  tested  in  two 
independent runs. 
The  study  was  completed  in  August  1997~ at which  time  the  data  on  the  20 coded 
chemicals were ~tatistically analysed:  - · 
Preliminary  review  Of the  results _of  the  study  demonstrate  that most chemicals  were  . 
correctly classified by the 4 participating laboratories, whether PIF or MPE were_ used to 
assess  phototoxic ·potential.  This  special  study  further  supp~rted the  finding- that  the .  -
3T3 NRU PT  test  a~curately  predicts  _the  phototoxic ._potential  of  chemicals, _  as 
-demonstrated in Phases I and II of the validation triaL- A full  report will be available in 
summer 1998.  ·  - -
Cu:rrently,  there  are  no  OECD test  guidelines  for  in  vivo  photoirritancy tests  as  the 
Secretariat  halted  proposals  for -such  gJ.lidelines,  pending  the, results  of the  ECV  AM 
validation  study.  A  draft  guid~line -incorporating.  the  standard  protocol  -for  the 
3T3 NRU PTtest will.be prepared during summer 1998, according to_OECD guidance on 
the preparation of  test guidelin~s.  -
14 Eye irritation 
Over the  last year the data analyses from  a number of validation studies have  become 
available.  However, none of the protocols have demonstrated reliable prediction1 under 
the conditions of the respective validation programme.  A  review of the qata obtained 
from  all  available studies is currently being .carried out by experts, for discussion at an 
ECVAM  workshop.in June 1998.  A meeting was held in London in  October 1997, in 
which aworking group was established to review the databases of  the following studies: 
•  the EU/HO study 
•  the COLIPA study 
•  the BgVV study 
•  the CTF  A study 
•  the JCIA study  -
•  the IRAG study 
A report from this study will be available by June 1998. 
Whilst  no  single  method  demonstrated  accurate  prediction  of eye  irritation,  several 
cosmetics companies employ a hierarchical approach to in vitro testing for. eye irritation, 
utilising a battery of  tests.  To Investigate the efficacy of  this approach, a  thorough review 
of hierarchical testing strategies is being carried out under the auspices of ECV AM; a 
report will Qe available in May 1998, for discussion at the ECV  AM workshop. 
ECV  AM are also leading a discussion on the concept of benchmarking ; comparison of 
the results obtained for new materials with a small number of  test materials bearing high 
quality data oii the toxic end-points of interest:  The discussion is aimed at defining the 
concept, identification of  its use, selection of  materials and availability of  data generated. 
· A report will be available in June 1998.  · 
CO  LIP A  sponsored  a  workshop  on  the  mechanisms of eye  irritation  in  Brighton  in 
October 1997. .  The  workshop  brought  together  thought~leading researchers  in  eye · 
·biology, ophthalmology and toxicology in order to identify a research programme aimed 
at developing mechanistically-based tests.  This workshop was very successful and w.ill 
enable CO  LIP  A to define a medium to long term research programme.  A report will be 
available in the summer of 1998. 
Percutaneous absorption 
As summarised in the last annual report, the regulatory acceptance of  in vitro methods for 
the measurement of  percutanc::ous absorption has been the topic of  great discussion,  The 
fact that an in vivo guideline has been concurrently proposed has further exacerbated the 
situation.  Following the. OECDIECV  AM meeting in Brussels in· early 1996, an expert 
sub-group  redrafted  the  in  vitro  test  guideline  for . percutaneous  absorption.  This 
guideline was forwarded to  the OECD co-ordinators in June 1996, accompanied by  in-:- . 
house data provided by CO  LIP  A members; supporting the reproducibility and predictivity 
of  the in vitro method.  .  · 
The  new  guidelines were  reviewed  by  OECD  Member  Countries,  as  well  as  the 
Commission services and industry.  All Member Countries supported the guidelines with· 
the  exception  of the  US  and ·Canada.  The  7th National ·Co-ordinators  meeting  in 
.  15 September 1996 agreed to  a workshop to discuss data supporting the validity of the in 
vitro method.  .  r  '  . 
.From the  dis~~ssions of the gth National Co--ordinators meeting in April 1997, the OECD 
drafted  a  summary  of the  status  of the  t~st guidelines.  The  su~inary  · proposed an 
OECD workshop on the acceptability of  the in vitro test guideline tobe held in th~ US in 
October 1997.  The aim  of the  workshop  was  to  discuss  the  database  supporting the 
validity of the in vitro method and to  agree.op~m the approach to be taken for the further 
work considered to be necessary to enable the draft in vitro guideline to be acceptable to 
all parties.  ·  · 
The workshop did not take place, but instead a Steering Committee meeting .Was held in 
the US  from  15-17 October 1997.  Agreement was reached on the need for a guidance 
document to accompany the two test guidelines (in vivo ane in vitro).  Also, comparable 
"acceptance criteria" must be applied to both the in vitro and the in vivo metho-dologies. 
Finally, it was proposed that the draft in  vitro guideline should be rewritten, to .include 
more details on:  ~ 
a) the rationale for the methodology  , 
b) the endpoints used, ahd their relevance and limitation~ 
c) the protocol  -
d) sources of  variability_ 
·e) ,ide!J.tification of reference chemicals/standards (selected on the basis of appropriate 
physico-chemical properties). 
The .data submitted by CO  LIP A were reviewed and it was agreed that these data were 
. valuable, although some clarifications and revisions were needed.  Other possible data 
sources (chemicals and p~sticides industries) were identified  . 
. The OECD Secretariat have proposed a schedule which will enable a  decision to be taken 
·about the acc.eptabilities of both the in vitro and in  vivo guidelines by September 1998. 
The OECD Secretariat is currently collating a huge literature database of references and. 
abstracts  on ·percutaneous  absorption  giving  comparisons  of the  in vitro  and  in  vivo 
methodologies.  The draft in vitro guideline is currently·under revision, and a draft of  the 
guidance document is in preparation; 
Skin irritancy 
An E·cv  AM skin irritation task  force was established_ in November ·1996.  The group was 
asked to prepare an ECV  AM report ·on the current status of alternative test development 
and validation in the field of skin irritation/corrosion and to identity_ any appropriate non-
. animal  tests  for  predicting human skin  irritation tbat could  be proposed .  as  candidate' 
methods for pre-validation/validation studies.  Meetings were held in December 1996 and 
. February 1997, a third meeting is planned for Jan~ary 1998.  The task force has discussed 
the testing strategy that was proposed at an OECD workshop on validation and regulatory 
acceptance  (Solna, · 1996)  and  has  reviewed  the  use  Qf. structure.:activity  relationship 
models, pH  and acid/alkali reserve measurements; in vitro test protocols and human patch 
testing. 
An ECV  AM workshop on skin irritation was held in November 1991 and discussed the 
use of humari keratinocytes arid human skin m<?dels  iri the prediction of  sk;in  irritation  . 
. 16 The group discussed the testing strategy that was proposed by an earlier OECD workshop 
on skin irritation and reviewed the use of structural-activity relationship mo~els, pH and 
acid/alkali  reserve measurements, in  vitro test protocol and human patch testing  ..  The 
recommendations of  this workshop wiJl be forwarded to the ECV AM taskforce. 
The meeting of the ECV  AM taskforce on skin irritation is-planned for January 1998 and 
will  involve  consideration of proposals  for  prevalidation and  validation  studies  to  be 
conducted during 1998/1999  . 
. As a result of the.above-mentioned OECD worksh9p on skin irritation, a protocol for an 
ethically approved 4-hour human patch test is currently under consideration as an OECD 
guideline. 
CO  LIP A published sets of  guidelines on the assessment  of  skin compatibility of  cosmetic 
finished  products  in  man  (during  l996) and -on  the  assessment of skin  tolerance  of 
potentially irritant cosmetic ingredients in man (du.ring 1997). 
Skin corrosivity 
This is  an  important first  step in any safety testing programme as  the  results of s~ch 
studies  will  ·often  determine  the  design  of the  safety  test  battery.  The  results  of a 
r  . 
prevalidation  study  on three  in  vitro  tests  for  skin corrosivity  were  published  as  an 
ECV  AM workshop report  in  1995.  Subsequently,  an ECV  AM  validation sttidy was 
planned, which was completed during 1997.  · 
The main objectives of  the validation study on in vitro  tests for skin corrosivity were to 
identify tests capable of  discrimina~ing corrosives from non-corrosives for selected types · 
of chemicals and/or all chemicals, and to determine Whether these tests could correctly 
. identify  knoWn  R35  (UN  packing  group  0 and  R34  (UN  packing  groups II  &  IIO 
-chemicals.  Four methods were evaluated in this study: 
•  EPISKIN (a human skin model)_ 
•  Skin
2 ZK 1350 corrosivity test- _ 
•  Transcutaneous electrical resistance in rat skin 
•  CORROSITEX (a physicochemical method) 
Each  test  was  conducted  in ·three  independent  laboratories.  and  a .  total  of 60  coded 
chemicals were tested (27 corrosive, 33 non-corrosive).  The test chemicals .fell under the 
following classification: 
11  organic acids 
10 organic bases 
9 neutral organics 
·5 phenols 
7 inorganic acids 
4 inorganic bases 
3 inorganic salts 
8 electrophiles 
3 surfactants 
The data demonstrated that the EPISKIN and rat skin TER protocols met the criteria 
concerning acceptable prediction r:-ates.  These two tests were considered to be accurate in 
distinguishing  between  corrosive  and  non-corrosive  chemicals.  All  tests  showed 
17 acceptable  intral~boratory and interlaboratory teprodu.cibility.  Importantly, the EPISKIN_. 
test proved CfTcctiyc  in identification of known R35/l  and R34/II and III  chemicals (EU 
risk phrases and UN packing groups). 
However, the Skin
2 test kit wa;  withdra~ from the market during the validation study. 
To  avoid  recommending the  usc  for  regulatory  testing of a specific· commercial human 
skin model  (EPlSKIN), ·a special  further  prcvalidation study  is  being conducted using 
EpiDerm, with ECV ~M  s_upport.  · 
Two manuscripts on this study have been submitted for publication . 
Scnsitisation ·  .  , .  .  . 
An ECVAM/COLIPA study investigating the induction of IL-l B expression in cultures 
of human skin dendritic cells" as' an endpoint for screening for potential was. initiated in 
·late 1997  (Interleukin~  1  B is a mediator of the. induction phase of  contact sensitisation and 
has been shqwn to  be increased within·minutes of application of allergens in some pre-
clinical experiments).  · 
~ 
In addition, an.ex vivo explant method· is under evaluation and a prevalidation study may 
.  1  •  ' 
be conducted during 1998 under contract with ECV  AM.  · 
Clinical testing of cosmetic products 
In early 1997, the second revision of  the SCC "Notes of guidance. for testing of cosmetic 
ingredients  for  their safety  evaluation" became available.  In these guidance notes the 
sec  stated  that  for  analysis  of potential . adverse  effects  of a  cosmetic  product' or . 
ingredient (in this sense adverse effects relate to skin irritation) observ-ations in human 
subj_ects should be used if  available.  · 
ln this respect, the Sec has worked to produce a.document on the- ethical considerations 
for clinical studies on cosmetic products  ~n human subjects.  The·  fi~al version -of these 
guidelines. will be available. in 1998.  The SCC expressed the opinion that, for ethical and 
scientific  reasons  in  general,  human  testing  should  only  be  carried  out  after  careful  . 
· scientific consideration.  The two key factors in the use of  dinical_trials is that: 
•  ·  Experiments on man cannot replace those on animals 
o  The purpose of  experiments on humans is to confirm findings on safety and to verify 
the acceptability and efficacy of  cosmetic products 
However, the SCC document does outline the value of clinical tests on cosmetics in the 
evaluation of  safety in use and perform~ce  of  such products; 
In a  separate  initiative,  ECVAM  produced. a  working  paper  on,- "The use ofhuman 
volunteers  in. cosll).etics  efficacy  and  safety  testing." · The  paper  described  res.earch 
projects  that  would  study  the  procedures  used  in  human  volunteer·  testing,  the  · 
measurements made and the equipment involved. 
At the Department of  Dermatology; University of  Pavia (Italy), an ECVAM-f}lnded study 
on the  quantification of alle_rgic  and  irritant reactions  induced by  cosmetics in human 
16 volunteers has taken place, which has analysed the  use. of both visual and  instrumental 
techniques.  The results from  this study will be available in  a report to  be published in 
early  1998.  AN  ECV AM  workshop, on the  utilisation of non-invasive  hiocngi!1ccring 
techniques in human .volunteer studies is planned for March 1998. 
An  ECV  AM-supported study on the integrated. usc of human data with results obtained 
from  other alternative methods. was made at the  University of Nottingham (UK), .in the 
FRAME Alternatives Laboratory.  Tht; study is now complete and a report is expected in 
earfy 1998. 
G.  STATISTICS 
According to Article 13 of  Council Directive 86/609/EEC (on the approximation of  laws, 
regulations and administrative provisions of  th~ Member States regarding the protection 
of  animals used for experimental and·other scientific purposes), Member States have the 
obligation to·collect, and periodically make publicly available, the statistical infonnation 
on the use of  animals in respect of:  · 
(a) ·the number and kinds of  animals used in experiments; 
(b)  the number of  animals, in selected categories, used in experiments 
(c)  the number of  animals, in selected categories, used in experiments required by 
'- legislation.  ·  · 
These data· shall be obtained on the basis of requests for authorisation and notifications 
received, and on the basis ofthe reports made, to the authorities of  the Member State. 
' 
Further  to  the  requirements  laid  down  in  this  Directive,  the  basic  C<?smetics 
Directive 761768/EC,  Miele 4 (i),  as  amended  by· the  6th  . amendment  Coun9il 
Directive 93/35/EEC, requires the Member States to collect additional information on the 
number and type of  experiments ·relating to cosmetic products carried out on animals. 
The Commission has  encountered difficulties in obtaining statistics relating to animal 
testing  in  cosmetics.  In  spite  of communications  from  the  Commission,  reminding 
Member States of their obligations and  urging  them to  supply  such statistics,  not  all 
Member States have been in a position to disclose data. Those data that have been made 
available· are given below: 
.. 1996 
.  -:  Ireland and Finland and Portugal confirmed that cosmetic products had riot been tested 
on  animals in their territories during 1996. 
- Germany confirmed that no finished cosmetic products had been tested on animals but 
could not comment ori the testing of  cosmetic ingredients.  · 
Since publication of the  1996 Annual  report,  the following  statistics  have  been made 
available: 
- Greece reported that no animals had been used for testing of substances used or to be 
used mai_nly in cosmetics.  · 
19' ', 
/ 
·- Ireland indicated that no animals were used for the testing of  cosmetics. 
- Denmark  submitted detailed  statistics demonstrating  that  a-total of 692animals had 
been used  to test products/substances used or intended to be u.sed mainly as cosmetics or 
toiletries. 
- Belgium  reported  that a total  of 58 animals  were  used for  testing materials· used  or 
destined to be used in cosmetic products during 1996. 
- The  UK  reported animal procedures involving  101 cosmetics, of which 85  were tests 
upon ingredients and  16 were tests on finished products.  A total of  280~ animals were 
used for testing purposes.  Ofth_ese 2551  (91  %) were for ingredients and 252 (9 %) were 
for finished products. 
At  the  end  of 1997;  'a  final  letter  was  sent  to  the  Permanent  Representations  of all  · 
Member States who  had  not supplied-data on  animal  usage  in cosmetic testing for  the 
pr<;~ious year~  The .communication stressed the  .. importance of these dat1:1  and  urged the 
Member States to comply with the provisions of the EU Cosmetics Directive.  Following . 
this  final  communication, the  Cqmmission will  initiate infringement measures  against 
.  tho~e Member  States  which  failed  to  rep~rt data  on .  animal  usage  in  th~ testing  of 
cosmetic products.  '· 
Despite  both .  verbal  and  written  requests  to  Member States  in early  1998,  reminding 
Member States ·Of their obligations in t4is respect, no  data were available pertaining to 
animal  experimentation  for  cosmetics'  during. 1997.  The  Commission  will  take 
·appropriate  measures  to  ensure  that  such  data  are  made  available. at  the  earliest 
opportunity.· 
Some  Member  States  have  taken  unilateral,  national.legislative  measures  regarding 
animal testing on .cosmetics. 
In  the  Netherlands,  the·  Experiments  on  Animals  Act  . entered  into  force  on 
5th February 1997.  This measure prohibits animaLexperimentation in the development of 
new  cosmetics  or  the  t.esting. of existing  cosmetics,  as  per .the  provisions  of the 
Commodities Act. 
In  November 1997, the UK announced an  end to cosmetic product testing on animals  . 
. The context of this announcement was that the  three  UK-based contract facilities  that 
previously .held licences to test cosmetic formula~ions on animals, agreed to give up these 
licences.  They voluntarily returned the licences to the Home Office.  Therefore, there are· 
no  longer ariy  facilities  in  the ·UK that are  authorised  to  carry out animal  testing  on 
finished cosmetic products.  ·  · . 
.  ' 
Germany also took measures to prohibit animal testing of cosmetics. · In November 1997 ·· 
the German Parliament passed a bill that placed a ban on animal  h~sting for 'the  purpos~s 
of development  of cosmetics.  This  biB entered  into  force  on  1st January 1.998  and  it 
effectively  prohibits  the  testing  of finished  products  or  ingredients.  However,  it  is 
possible for derogations to be granted. 
20 For cases in which finished product testing has been prohibhed, the distinction between a 
· finished product and a combination of ingredients has not been defined. 
It  is  important  to  note  that  whilst  national· hans prohibit animal  testing on  a  Member 
State's territory, this may not actually represent' a true r~duction in animal usage.  Rather~ 
the tests could be carried out in an alternative Member State or in a Third Country.  This 
could also be the case in those examples in which Member States have reported that no 
tests  were  conducted  on  their  territory.  Further,  it  is  pertinent  to  note  that  these 
prohibitions are placed .on  the actual animal test rather than on a marketing ban ·of the 
cosmetic product.  · 
li.  CONCLUSIONS 
1997 saw the completion of several experimental programmes aimed at the development 
of novel alternative methods  to  animal testing.  Unfortunately,  efforts to  date did  not 
yield  the  results that were._hoped  for.  Whilst some promising innovations have  c~me 
from some of these programmes, the validation of new methods across the range of  toxic 
ehd-points did not prove to be possible.  Following an exhaustive scientific review of  the 
status of alternative methods to  animal testing in  1997, the Commission put forward a 
postponement of  the ban in the absence of  scientifically validated alternative methods. 
Since then, experts in this field  have continued to  analyse the existing data and  work 
towards a better mechanistic understanding of the science underlying these toxic end-
points .. New programmes have been and are being developed to build on the progress 
made thus far. 
Previously, there has been a demand for a timetable for the development and validation 
of  alternatives in the Commission's annual reports.  However, the predicti~n of  a realistic 
timetable for basic research and method development of this kind is simply not feasible. 
Research into biological systems is subject to variability and practical problems that must 
be resolved in  a step-wise manner if research is to be conducted in a scientifically valid 
and appropriate fashion.  · 
This report demonstrates that the submission of statistics on animal usage in  the field of 
cosmetics remains problematic for  some Member States.  Obviously, the Commission 
remains at the disposal of all parties to help resolve any practical issues that arise as a 
result  of this  obligation,. and  will  continue  to  press  Member  States  to  fulfil  ·these 
obligations.  In cases where·Member States remain unable to  meet the requirements· of 
. the  Cosmetics  Directive  in  terms  of submission  of these  data,  the ·Commission  is 
preparing legislative action in the form of  infringement procedures. 
Clearly, the cosmetics industry has taken a lead role in the development of alternative 
methods to  animal testing, committing· significant funds  and scientific resources.  The 
resources that the cosmetics industry have given to this issue are disproportionate to  its 
use  of animals  for  experimentation.  . However,  the  industry .  ~ontinues to  support  the 
concepts of reduction, refinement and replacement of animal use in the safety testing of 
its  products and ingredients.  Following the  completion of the  experimental  phase of 
several validation studies, experts from the cosmetics and chemical sectors are working 
to develop a second round of  research programmes. 
21 The  Commission  services  have  allocated · significant  resources  to  the , development, 
validation and acceptance of alternative methods to animaJ testing.  Most notably, in the· 
past year ECVAM has dedicated a large proportion of its attention to this industry sector. 
In  the  futu!e,  the  Commission  services  will  collaborate  and  pool  resources  in  these -
efforts,  particularly  in  the  work  programmes of its  scientific committees.  Lastly,  it  is 
proposed 'that the 5
1
h Framework Programme will provide the potential for the funding of-
new and innovative proposals in the development of  novel methods.  · 
Following the recent re-organisation of some of the Commission services, new wor~ing 
practices  have  been· established  and  the·  collaboration  between  scientists  from  the 
Commission,  M~mber States  and  Industry- coritinue  to  strengthen.  Through  the 
development of ·short,  medium and  long-term research proposals it will  be possible to 
make ·significant  progress  iri  this  challenging . scientific  issue  and  meet  the  common 
objective.of a meaningful reduction in animal experimentation. 
22 . I.. GLOSSARY. OF ABBREVIATIONS 
BgVV 
CO  LIP  A 
CTFA 
··ECVAM 
EU/HO 
ERUAIT 
ESAC 
EU 
GM-CFU 
IRAG 
IV TIP 
JCIA 
NRU 
OECD 
SCAAT 
sec 
SCCNFP 
.SIS 
SME 
uv 
ZEBET 
Bundesinstitut flir gesundheitlichen Verbraucherschutz und. 
·. Veterinarmedizin 
Comite de Liaison Europeen des Industrie Cosmetiques, des 
Produits de Toilette et de Ia Parfumerie (The European Cosmetic 
Toiletry and Perfumery Association)  . 
Cosmetic, Toiletry and Fragrance Association (USA) 
European Centre for the Validation of  Alternative Methods 
European Union/Home Office 
European Research Group for Alternatives in Toxicity Testing 
ECV  AM Sci~ntific Advisory Committee 
European Union 
Granulocyte-macrophage-colony forming unit 
Interagency Regulatory Alternatives Group 
. In vitro Testing Industrial Platform 
Japanese Cosmetic Industry Association 
Neutral Red. Uptake 
Organisation for Economic Co-operation and Development 
Steering Committee on Alternatives to Animal Testing 
Scientific Committee on Cosmetology 
Scientific Committee on Cosmetics and Non-food products 
. Scientific Information Service 
Small and Medium Sized Enterprises 
Ultra Violet 
· Zentralstelle zur Erfassung und Bewertung von Ersatz und 
Erganzungsmethoden zum Tierversuch im Bundesgesundheitsamt 
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